Blog
RSS FeedPosted by Michael Wonder on 08 Sep 2021
NICE draft guidance recommends apalutamide for treating prostate cancer
8 September 2021 - NICE has today published final draft guidance which now recommends apalutamide (Erleada; Janssen) plus androgen deprivation therapy ...
Posted by Michael Wonder on 27 Aug 2021
NICE ‘no’ for Janssen’s Darzalex combo
27 August 2021 - NICE has published draft guidance stating that it does not recommend Janssen’s Darzalex (daratumumab) plus bortezomib, ...
Posted by Michael Wonder on 25 Aug 2021
NICE publishes appraisal guidance on new medicine for patients with biliary tract cancer
25 August 2021 - Pemigatinib (Pemaryze, Incyte) has a conditional marketing authorisation for the treatment of adults with locally advanced or ...
Posted by Michael Wonder on 18 Aug 2021
NICE publishes final guidance on the use of a topical gel for patients with a rare cancer
18 August 2021 - Chlormethine gel for is used for the treatment of patients with mycosis fungoides type cutaneous T-cell lymphoma. ...
Posted by Michael Wonder on 12 Aug 2021
NICE draft guidance recommends abemaciclib for advanced breast cancer
12 August 2021 - NICE has today published draft guidance which recommends a twice daily pill abemaciclib (Verzenios; Eli Lilly) as ...
Posted by Michael Wonder on 22 Jul 2021
Patients with rare bile duct cancer set to benefit from life extending treatment
22 July 2021 - Some people who have a rare form of bile duct cancer are set to benefit from life-extending ...
Posted by Michael Wonder on 16 Jul 2021
Ledaga recommended by NICE for rare type of lymphoma
16 July 2021 - NICE has recommended Recordati Rare Diseases and Helsinn Healthcare’s Ledaga for a type of lymphoma that ...
Posted by Michael Wonder on 16 Jul 2021
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
16 July 2021 - NICE has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the ...
Posted by Michael Wonder on 15 Jul 2021
Another month, another terminated appraisal of a cancer medicine
14 July 2021 - This time it is a medicine for adults and children with acute lymphoblastic leukaemia. ...
Posted by Michael Wonder on 07 Jul 2021
Enzalutamide for men with hormone sensitive metastatic prostate cancer
7 July 2021 - NICE publishes final guidance on a new indication for Xtandi. ...
Posted by Michael Wonder on 07 Jul 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
7 July 2021 - Final guidance published after appeal. ...
Posted by Michael Wonder on 14 Jun 2021
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...
Posted by Michael Wonder on 14 Jun 2021
NICE to reassess Kyowa Kirin’s Poteligeo
14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...
Posted by Michael Wonder on 08 Jun 2021
NICE recommends Tecentriq for first-line NSCLC
7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...